skip to content

Network of Trophoblastic Diseases of Quebec

Information and support for professionals and patients

  • Mission of the RMTQExpand
    • Operation – RMTQ
    • Team – RMTQ
    • Software – RMTQ
    • Software development
    • Statistics
  • ProfessionalsExpand
    • DiagnosticExpand
      • Clinical classification
      • Post-molar GTN
      • Quiescent GTD
    • ßhCGExpand
      • Elevated ßhCG
      • non-GTN tumor hCG
      • Differential dx hCG
      • ßhCG – normal pregnancy
    • FIGO stages and scoresExpand
      • FIGO Stadiums
      • FIGO score
      • GTN Risk Levels
    • Pathology and geneticsExpand
      • Principles of Genetics
      • Origins and phenotypes
      • Moles and abortions
      • EPS, PSN and GTN
    • GTD in numbers
  • GuidelinesExpand
    • ISSTD et al. 2025
    • SOGC/GOC DirectiveExpand
      • Practice Changes
      • Key messages
      • Summary declarations
      • Recommendations
    • Hydatidiform molesExpand
      • Partial/complete moles
      • Post mole follow-up
      • Moles and pregnancies
    • NeoplasiasExpand
      • Low risk GTN
      • GTN ultra/high risk
      • Post-GTN follow-up
      • Recurrent GTNs
    • PSTT and ETT
    • ChemotherapyExpand
      • Monochemotherapy
      • EMA-CO and EMA-EP
      • Polychemotherapies
      • CHUM Chemo Protocols
  • ResearchExpand
    • Rima Slim PhD Lab.
    • Protocols – RMTQ
    • Publications – RMTQ
    • Abbreviations
    • Useful links
  • PatientsExpand
    • Nurse Coordinator
    • Babies – RMTQ
    • Hydatidiform mole – FAQ
    • Malignant disease – FAQ
    • Testimonials
  • French
Facebook Linkedin
Network of Trophoblastic Diseases of Quebec
Information and support for professionals and patients

Protocoles de chimiothérapie CHUM

  • Méthotrexate IM
  • Dactinomycine
  • EMA-CO haut risque
  • EMA-EP haut risque
  • EMA-EP SNC
  • Induction EP faible dose
  • Pembrolizumab
Méthotrexate IMTélécharger
DactinomycineTélécharger
EMA-CO haut risqueTélécharger
EMA-EP haut risqueTélécharger
EMA-EP SNCTélécharger
Induction EP faible doseTélécharger
PembrolizumabTélécharger

Modified on 12/23/2023

Tropho News

6 new deleterious variants identified in androgenetic hydatidiform moles!

Read more ...
FIGO score calculation Declare your patient To contact us
  • Make a donation
  • Sitemap
  • Legal Notice
  • Confidentiality

Quebec badge

Eco -responsible accommodation badge

© 2026 Réseau des Maladies Trophoblastiques du Québec - Tous droits réservés

Scroll to top
  • Mission of the RMTQ
    • Operation – RMTQ
    • Team – RMTQ
    • Software – RMTQ
    • Software development
    • Statistics
  • Professionals
    • Diagnostic
      • Clinical classification
      • Post-molar GTN
      • Quiescent GTD
    • ßhCG
      • Elevated ßhCG
      • non-GTN tumor hCG
      • Differential dx hCG
      • ßhCG – normal pregnancy
    • FIGO stages and scores
      • FIGO Stadiums
      • FIGO score
      • GTN Risk Levels
    • Pathology and genetics
      • Principles of Genetics
      • Origins and phenotypes
      • Moles and abortions
      • EPS, PSN and GTN
    • GTD in numbers
  • Guidelines
    • ISSTD et al. 2025
    • SOGC/GOC Directive
      • Practice Changes
      • Key messages
      • Summary declarations
      • Recommendations
    • Hydatidiform moles
      • Partial/complete moles
      • Post mole follow-up
      • Moles and pregnancies
    • Neoplasias
      • Low risk GTN
      • GTN ultra/high risk
      • Post-GTN follow-up
      • Recurrent GTNs
    • PSTT and ETT
    • Chemotherapy
      • Monochemotherapy
      • EMA-CO and EMA-EP
      • Polychemotherapies
      • CHUM Chemo Protocols
  • Research
    • Rima Slim PhD Lab.
    • Protocols – RMTQ
    • Publications – RMTQ
    • Abbreviations
    • Useful links
  • Patients
    • Nurse Coordinator
    • Babies – RMTQ
    • Hydatidiform mole – FAQ
    • Malignant disease – FAQ
    • Testimonials
  • French
Search